All Articles

Researchers report higher overall response rate, median duration of response, and median progression-free survival in treatment-naïve patients with a MET exon 14 skipping mutation compared with previously treated patients. Read More ›

Researchers reported improved overall survival in patients with nonsquamous non–small-cell lung cancer with EGFR mutations. Read More ›

Tarloxotinib treatment was well tolerated and sizeable percentages of patients in both study cohorts achieved either partial response or stable disease. Read More ›

Osimertinib shows promise as an adjuvant treatment for patients with stage IB to IIIA EGFR mutation–positive NSCLC. Read More ›

Treatment with dabrafenib and trametinib produced similar benefits in pretreated and treatment-naïve patients. Read More ›

Improved progression-free survival and overall survival in patients who received upfront stereotactic radiotherapy and TKI treatment should prompt additional study. Read More ›

Previously untreated patients and those who had received prior intracranial radiotherapy responded to selpercatinib treatment. Read More ›

Treatment was well tolerated and also associated with delayed progression in previously treated patients with NSCLC and MET^Amp/Ex14Δ. Read More ›

Dual treatment with ramucirumab and erlotinib produced similar results in patients with ex21 and ex19 mutations. Read More ›

This study reports on the ZENITH20-2 cohort of previously treated patients with advanced NSCLC and an HER2 exon 20 insertion mutation. Read More ›